In September, the 33rd National Academic Conference of China National Tuberculosis Association was grandly held in Qingdao. On the first day of registration, the anti-tuberculosis FDC standard use and management expert seminar hosted by the China National Tuberculosis Association and co-organized by Shenyang Hongqi Pharmaceutical Co., Ltd. will be held on the evening of September 27, 2021.

    The meeting invited Zhao Yanlin, Director of the Tuberculosis Prevention and Control Center of China CDC, Chen Mingting, Deputy Director, Chief Physician Zhou Lin, and Researcher Wang Ni; Lu Shuihua, Director of the Tuberculosis Department of Shanghai Public Health Clinical Center, Zhang Zhongfa, Director of Shandong Provincial Public Health Clinical Center, Liu Jie, deputy dean of the Second People’s Hospital of Nanjing, Zhang Xia, deputy dean of Nanjing Second People’s Hospital, Wu Yuqing, director of Jiangxi Chest Hospital, and Han Wenge, director of Weifang Second Hospital, have attracted more than one hundred first-line doctors, Enterprise representatives and partners discussed the standardized use of FDC nationwide. Liu Jianjun, chairman of the China Tuberculosis Association, and Yang Bo, general manager of Hongqi Pharmaceutical, a leading company in the field of anti-tuberculosis, attended the conference and delivered speeches.

   In his speech, Liu Jianjun pointed out that the continuous supply and management of high-quality anti-tuberculosis drugs is an important guarantee for the development of patient-centered treatment management and care services. my country’s "Twelfth Five-Year" TB planning goal clearly stated that the nationwide use rate of anti-tuberculosis FDC in counties will reach 100%, and it will be achieved on schedule. However, there are still many problems in the use of FDC. In 2021, less than 60% of pulmonary tuberculosis patients in the country have used anti-tuberculosis FDC. A large number of studies at home and abroad have proved that FDC can improve the compliance of patients with treatment. Simultaneous use of FDC can ensure the combination of drugs, thereby controlling the occurrence of drug-resistant tuberculosis. Before the full promotion of FDC in the "Twelfth Five-Year Plan", my country has done a lot of applied research to prove the quality and safety of domestic anti-tuberculosis FDC. In the "three-in-one" model, designated tuberculosis medical institutions are the key to increasing the utilization rate of FDC. At the same time, the procurement, supply and management model of drugs should be constantly improved according to different times. "

    Yang Bo, general manager of Hongqi Pharmaceutical, said that after years of research and production, Shenyang Hongqi Pharmaceutical's fixed-dose combination anti-tuberculosis drugs are fully formulated in accordance with the standards determined by the World Health Organization and have shown very good effects and safety in clinical applications. Especially in terms of medication compliance and reduction of drug resistance, it has huge medical economic value and social benefits, and it is a drug recommended by the national disease prevention and control plan. As one of the national key tuberculosis drug manufacturers, Shenyang Hongqi Pharmaceutical has the responsibility to provide qualified and high-quality products and make due contributions to ending tuberculosis by 2035.

    Subsequently, four participating experts, Zhou Lin, Lu Shuihua, Wu Yuqing, and Han Wenge, respectively shared their work experience, clinical experience and new FDC technology frontiers from the perspectives of planning management, research progress, and clinical application. Provide guidance and follow for clinicians across the country to understand and use FDC.

    At the end of the conference, clinicians from all over the country conducted academic exchanges and heated discussions on the hot and difficult issues of using FDC, and the atmosphere was lively. The on-site experts enlighten each other and build consensus through various forms such as theory teaching, skill sharing and case discussion. At the end of the meeting, Director Zhao Yanlin made a summary for the conference. He said that the use of FDC can better improve patient compliance, and that FDC should be widely and standardized in clinical use.

This conference adheres to the concept of openness, cooperation and development, and aims to let more clinicians understand FDC and use FDC to promote tuberculosis prevention and treatment and people's health to a new level, and contribute to the realization of the goal of ending tuberculosis!